4506.Tライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (26 4月 2024 @ 15:15):

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally...

Stats
本日の出来高	1.42M
平均出来高	3.35M
時価総額	162.89B
EPS	¥0 ( 2024-01-31 )
次の収益日	( ¥-323.99 ) 2024-05-13
Last Dividend	¥7.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	-0.940
ATR14	¥0.448 (0.11%)

ボリューム相関

長: 0.25 (neutral)

短: 0.26 (neutral)

Signal:(64.01) Neutral

Sumitomo Pharma Co., Ltd. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sumitomo Pharma Co., Ltd. 相関 - 通貨/商品

0.66
( moderate )

0.74
( moderate )

0.55
( weak )

0.75
( moderate )

-0.02
( neutral )

-0.61
( weak negative )

Sumitomo Pharma Co., Ltd. 財務諸表

Annual	2022
収益:	¥555.54B
総利益:	¥376.63B (67.79 %)
EPS:	¥-187.55

FY	2022
収益:	¥555.54B
総利益:	¥376.63B (67.79 %)
EPS:	¥-187.55

FY	2022
収益:	¥560.04B
総利益:	¥402.91B (71.94 %)
EPS:	¥102.19

FY	2021
収益:	¥515.95B
総利益:	¥378.18B (73.30 %)
EPS:	¥141.50

Financial Reports:

No articles found.

Sumitomo Pharma Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥14.00 (N/A)	¥0 (N/A)	¥7.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Sumitomo Pharma Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥4.75	2000-03-28
Last Dividend	¥7.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	47	--
Total Paid Out	¥382.25	--
Avg. Dividend % Per Year	0.00%	--
Score	1.47	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-07-03)

¥6.79 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

1.47

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
7981.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7214.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
6460.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
5480.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4463.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
3649.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
2904.T	Ex Dividend Junior	2024-06-27	Annually	0.00%
1719.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
9763.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
8842.T	Ex Dividend Knight	2024-01-30	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.526	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.164	1.200	-5.46	-6.56	[0 - 0.3]
returnOnEquityTTM	-0.440	1.500	-6.00	-9.00	[0.1 - 1]
payoutRatioTTM	-0.0161	-1.000	-0.161	0.161	[0 - 1]
currentRatioTTM	0.627	0.800	-1.864	-1.491	[1 - 3]
quickRatioTTM	0.333	0.800	-2.75	-2.20	[0.8 - 2.5]
cashRatioTTM	0.0866	1.500	-0.630	-0.945	[0.2 - 2]
debtRatioTTM	0.389	-1.500	3.52	-5.29	[0 - 0.6]
interestCoverageTTM	-8.87	1.000	-4.40	-4.40	[3 - 30]
operatingCashFlowPerShareTTM	-693.01	2.00	-10.00	-10.00	[0 - 30]
freeCashFlowPerShareTTM	-728.72	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	1.199	-1.500	5.20	-7.81	[0 - 2.5]
grossProfitMarginTTM	0.599	1.000	3.34	3.34	[0.2 - 0.8]
operatingProfitMarginTTM	-0.536	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.669	1.000	-4.83	-4.83	[0.2 - 2]
assetTurnoverTTM	0.312	0.800	-1.256	-1.005	[0.5 - 2]
Total Score				-5.81

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.938	1.000	-0.196	0	[1 - 100]
returnOnEquityTTM	-0.440	2.50	-3.86	-9.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-728.72	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-693.01	2.00	-10.00	-10.00	[0 - 30]
payoutRatioTTM	-0.0161	1.500	-0.161	0.161	[0 - 1]
pegRatioTTM	-2.71	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.834	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-5.01

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.